Corrigendum: SIKs control osteocyte responses to parathyroid hormone (Nature Communications (2017) 7 (13176) DOI: 10.1038/ncomms13176);SIKs control osteocyte responses to parathyroid hormone

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wein, Marc N ^a   Liang, Yanke ^a   Goransson, Olga ^b   Sundberg, Thomas B ^c   Wang, Jinhua ^a   Williams, Elizabeth A ^a   O'Meara, Maureen J ^a   Govea, Nicolas ^a   Beqo, Belinda ^a   Nishimori, Shigeki ^a   Nagano, Kenichi ^d   Brooks, Daniel J ^a,e   Martins, Janaina S ^a   Corbin, Braden ^a   Anselmo, Anthony ^a   Sadreyev, Ruslan ^a   Wu, Joy Y ^f   Sakamoto, Kei ^g,k   Foretz, Marc ^h   Xavier, Ramnik J ^a,c,i   Baron, Roland ^a,d   Bouxsein, Mary L ^a,e   Gardella, Thomas J ^a   Divieti Pajevic, Paola ^j   Gray, Nathanael S ^a   Kronenberg, Henry M ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b LUND UNIVERSITY   (Sweden)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

^h INSTITUT COCHIN   (France)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j BOSTON UNIVERSITY   (United States)

^k NESTLÉ RESEARCH CENTER   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CRTC2 PROTEIN; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PEPTIDES AND PROTEINS; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; RNA; SALT INDUCIBLE KINASE; SCLEROSTIN; UNCLASSIFIED DRUG; YKL 05 093; YKL 05 099; CRTC2 PROTEIN, MOUSE; GLYCOPROTEIN; HDAC5 PROTEIN, MOUSE; HISTONE DEACETYLASE; ISOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SALT-INDUCIBLE KINASE-2, MOUSE; SMALL INTERFERING RNA; SOST PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

BONE; ENZYME; ENZYME ACTIVITY; HORMONE; INHIBITION; INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; GENE REPRESSION; HORMONAL REGULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCYTE; PROTEIN LOCALIZATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE; BONE DEVELOPMENT; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; NUCLEOCYTOPLASMIC TRANSPORT; PHOSPHORYLATION; PRIMARY CELL CULTURE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BONE AND BONES; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HISTONE DEACETYLASES; HUMANS; MICE; MICE, KNOCKOUT; OSTEOCYTES; OSTEOGENESIS; PARATHYROID HORMONE; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RANK LIGAND; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84992061004     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14745     Document Type: Erratum

References (70)

1. Harvey, N., Dennison, E. & Cooper, C. Osteoporosis: impact on health and economics. Nat. Rev. Rheumatol. 6, 99-105 (2010).
2. Bonewald, L. F. The amazing osteocyte. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 26, 229-238 (2011).
3. Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231-1234 (2011).
4. Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235-1241 (2011).
5. Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179-192 (2013).
6. McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412-20 (2014).
7. Cheloha, R. W., Gellman, S. H., Vilardaga, J. P. & Gardella, T. J. PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat. Rev. Endocrinol. 11, 712-724 (2015).
8. Keller, H. & Kneissel, M. SOST is a target gene for PTH in bone. Bone 37, 148-158 (2005).
9. Rhee, Y. et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 26, 1035-1046 (2011).
10. Kramer, I., Loots, G. G., Studer, A., Keller, H. & Kneissel, M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 25, 178-189 (2010).
11. Saini, V. et al. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J. Biol. Chem. 288, 20122-20134 (2013).
12. Fu, Q., Jilka, R. L., Manolagas, S. C. & O'Brien, C. A. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 277, 48868-48875 (2002).
13. Fu, Q., Manolagas, S. C. & O'Brien, C. A. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol. Cell Biol. 26, 6453-6468 (2006).
14. Kim, S., Yamazaki, M., Shevde, N. K. & Pike, J. W. Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers. Mol. Endocrinol. 21, 197-214 (2007).
15. Spatz, J. M. et al. The Wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J. Biol. Chem. 290, 16744-16758 (2015).
16. Wein, M. N. et al. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 30, 400-411 (2015).
17. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32-42 (2009).
18. Parra, M. & Verdin, E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr. Opin. Pharmacol. 10, 454-460 (2010).
19. Altarejos, J. Y. & Montminy, M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat. Rev. Mol. Cell Biol. 12, 141-151 (2011).
20. Berdeaux, R. et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat. Med. 13, 597-603 (2007).
21. Sasagawa, S. et al. SIK3 is essential for chondrocyte hypertrophy during skeletal development in mice. Development 139, 1153-1163 (2012).
22. Walkinshaw, D. R. et al. The tumor suppressor kinase LKB1 activates the downstream kinases SIK2 and SIK3 to stimulate nuclear export of class IIa histone deacetylases. J. Biol. Chem. 288, 9345-9362 (2013).
23. Sundberg, T. B. et al. Development of chemical probes for investigation of salt-inducible kinase function in vivo. ACS Chem. Biol. 11, 2105-2111 (2016).
24. Obri, A., Makinistoglu, M. P., Zhang, H. & Karsenty, G. HDAC4 integrates PTH and sympathetic signaling in osteoblasts. J. Cell Biol. 205, 771-780 (2014).
25. Lu, Y. et al. DMP1-targeted Cre expression in odontoblasts and osteocytes. J. Dent. Res. 86, 320-325 (2007).
26. McKinsey, T. A., Zhang, C. L., Lu, J. & Olson, E. N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408, 106-111 (2000).
27. Grozinger, C. M. & Schreiber, S. L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl Acad. Sci. USA 97, 7835-7840 (2000).
28. Taniguchi, M. et al. Histone deacetylase 5 limits cocaine reward through cAMP-induced nuclear import. Neuron 73, 108-120 (2012).
29. Baertschi, S. et al. and IIa histone deacetylases have opposite effects on sclerostin gene regulation. J. Biol. Chem. 289, 24995-25009 (2014).
30. Wu, J. Y. et al. Gsalpha enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. The J. Clin. Investig. 121, 3492-3504 (2011).
31. Fulzele, K. et al. Myelopoiesis is regulated by osteocytes through Gsalpha-dependent signaling. Blood 121, 930-939 (2013).
32. Bonnet, N., Conway, S. J. & Ferrari, S. L. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc. Natl Acad. Sci. USA 109, 15048-15053 (2012).
33. Saidak, Z. et al. increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice. J. Endocrinol. 223, 25-33 (2014).
34. Kozhemyakina, E., Cohen, T., Yao, T. P. & Lassar, A. B. Parathyroid hormone-related peptide represses chondrocyte hypertrophy through a protein phosphatase 2A/histone deacetylase 4/MEF2 pathway. Mol. Cell Biol. 29, 5751-5762 (2009).
35. Wang, B. et al. A hormone-dependent module regulating energy balance. Cell 145, 596-606 (2011).
36. Henriksson, E. et al. The AMPK-related kinase SIK2 is regulated by cAMP via phosphorylation at Ser358 in adipocytes. Biochem. J. 444, 503-514 (2012).
37. Henriksson, E. et al. SIK2 regulates CRTCs, HDAC4 and glucose uptake in adipocytes. J. Cell Sci. 128, 472-486 (2015).
38. Patel, K. et al. The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. Nat. Commun. 5, 4535 (2014).
39. Yang, D., Guo, J., Divieti, P., Shioda, T. & Bringhurst, F. R. CBP/p300-interacting protein CITED1 modulates parathyroid hormone regulation of osteoblastic differentiation. Endocrinology 149, 1728-1735 (2008).
40. Galli, C. et al. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 149, 146-153 (2008).
41. Kim, S., Yamazaki, M., Zella, L. A., Shevde, N. K. & Pike, J. W. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol. Cell Biol. 26, 6469-6486 (2006).
42. Onal, St M., John, H. C., Danielson, A. L. & Pike, J. W. Deletion of the distal Tnfsf11 RL-D2 enhancer that contributes to PTH-mediated RANKL expression in osteoblast lineage cells results in a high bone mass phenotype in mice. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 31, 416-429 (2015).
43. Clark, K. et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl Acad. Sci. USA 109, 16986-16991 (2012).
44. Sundberg, T. B. et al. Small-molecule screening identifies inhibition of saltinducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc. Natl Acad. Sci. USA 111, 12468-12473 (2014).
45. Kronenberg, H. M. Developmental regulation of the growth plate. Nature 423, 332-336 (2003).
46. Bergwitz, C. & Juppner, H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Ann. Rev. Med. 61, 91-104 (2010).
47. Pacifici, R. Role of T cells in the modulation of PTH action: physiological and clinical significance. Endocrine 44, 576-582 (2013).
48. Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513, 100-104 (2014).
49. Leupin, O. et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 22, 1957-1967 (2007).
50. St John, H. C., Hansen, S. J. & Pike, J. W. Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D or TGFbeta responsiveness. J. Steroid Biochem. Mol. Biol. S0960-0760, 30063-30067 (2015).
51. Li, C. et al. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression. Ann. N. Y. Acad. Sci. 1364, 62-73 (2015).
52. Shimizu, E., Selvamurugan, N., Westendorf, J. J., Olson, E. N. & Partridge, N. C. HDAC4 represses matrix metalloproteinase-13 transcription in osteoblastic cells, and parathyroid hormone controls this repression. J. Biol. Chem. 285, 9616-9626 (2010).
53. Haberland, M. et al. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol. Cell Biol. 27, 518-525 (2007).
54. Kramer, I., Baertschi, S., Halleux, C., Keller, H. & Kneissel, M. Mef2c deletion in osteocytes results in increased bone mass. J.Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 27, 360-373 (2012).
55. Tu, X. et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 50, 209-217 (2012).
56. Weir, E. C. et al. Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc. Natl Acad. Sci. USA 93, 10240-10245 (1996).
57. Martowicz, M. L., Meyer, M. B. & Pike, J. W. The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers. J. Cell. Biochem. 112, 2030-2045 (2011).
58. Horike, N. et al. Downregulation of SIK2 expression promotes the melanogenic program in mice. Pigm. Cell Melanoma Res. 23, 809-819 (2010).
59. Sasaki, T. et al. SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron 69, 106-119 (2011).
60. Popov, S. et al. Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake. PLOS ONE 9, e95771 (2014).
61. Park, J. et al. SIK2 is critical in the regulation of lipid homeostasis and adipogenesis in vivo. Diabetes 63, 3659-3673 (2014).
62. Sakamaki, J. et al. Role of the SIK2-p35-PJA2 complex in pancreatic beta-cell functional compensation. Nat. Cell Biol. 16, 234-244 (2014).
63. Yahara, Y. et al. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice by inhibiting Sik3. Nat. Commun. 7, 10959 (2016).
64. Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702 (1991).
65. Dai, X. M. et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111-120 (2002).
66. Chang, S. et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell Biol. 24, 8467-8476 (2004).
67. Kim, M. S. et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J. Neurosci.: Off. J. Soc. Neurosci. 32, 10879-10886 (2012).
68. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
69. Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 25, 1468-1486 (2010).
70. Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 28, 2-17 (2013).